Literature DB >> 14740977

Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest.

Anesa Ahamad1, Craig W Stevens, W Roy Smythe, Zhongxing Liao, Ara A Vaporciyan, David Rice, Garrett Walsh, Thomas Guerrero, Joe Chang, Brent Bell, Ritsuko Komaki, Kenneth M Forster.   

Abstract

PURPOSE: Malignant pleural mesothelioma often recurs locally in spite of aggressive resection by extrapleural pneumonectomy and conventional radiotherapy. This may be due to failure to recognize the extent of clinical target volume (CTV) or suboptimal dose delivery to a target that abuts the heart, esophagus, liver, lung, kidney, and spinal cord. We report how these geometric/dosimetric constraints were overcome by exploiting intensity-modulated radiotherapy in the first cohort patient.
MATERIALS AND METHODS: Twenty-eight patients who had undergone extrapleural pneumonectomy were treated with intensity-modulated radiotherapy. The CTV included the surgically violated inner chest wall, insertion of diaphragm, pleural reflections, and deep margin of the incision. CTV delineation was facilitated by intraoperative radio-opaque marking. Motion was assessed. CTV doses were 45-50 Gy with boosts taken to 60 Gy.
RESULTS: Despite the large, irregular CTV (median, 4151 cc; range, 2667-7286 cc), an average of 97% of the CTV was covered to the target dose (range, 92%-100%). Respiratory motion was minimal because of immobility of the prosthetic diaphragm. Normal tissue dose constraints were met. The commonest effects were nausea/vomiting (89%) and dyspnea (80%). Esophagitis was absent (59% of patients) or mild (34% grade 1/2). At median follow-up of 9 months (range, 5-27 months), local control within the contoured target was 100%. One-year survival, disease-specific survival, and disease-free survival are 65%, 91%, and 88%, respectively.
CONCLUSIONS: Intensity-modulated radiotherapy after extrapleural pneumonectomy is tolerable and seems effective, at least at this early point. As local control improves, systemic metastases become more common, and it may be appropriate to add novel agents to further improve the therapeutic ratio.

Entities:  

Mesh:

Year:  2003        PMID: 14740977     DOI: 10.1097/00130404-200311000-00008

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  22 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma.

Authors:  Kenichi Okubo; Makoto Sonobe; Takuji Fujinaga; Tsuyoshi Shoji; Hiroaki Sakai; Ryo Miyahara; Toru Bando; Hiroshi Date; Keiko Shibuya; Masahiro Hiraoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-11-12

4.  Wide complex ventricular tachycardia presenting sign of metastatic pleural mesothelioma.

Authors:  Ashmeet Bhatia; Tokunbo Ajayi
Journal:  BMJ Case Rep       Date:  2014-04-25

Review 5.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

Review 6.  Local and systemic therapies for malignant pleural mesothelioma.

Authors:  Daniel Gomez; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 7.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

8.  Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.

Authors:  Egesta Lopci; Paolo Andrea Zucali; Giovanni Luca Ceresoli; Matteo Perrino; Laura Giordano; Letizia Gianoncelli; Elena Lorenzi; Maria Gemelli; Armando Santoro; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-18       Impact factor: 9.236

Review 9.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

Review 10.  The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.

Authors:  Miranda Ashton; Noelle O'Rourke; Suzanne Currie; Andreas Rimner; Anthony Chalmers
Journal:  Radiother Oncol       Date:  2017-08-28       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.